MARKET

ONC

ONC

BeOne Medicines Ltd.
NASDAQ
252.14
+1.84
+0.74%
After Hours: 252.14 0 0.00% 16:20 07/14 EDT
OPEN
250.00
PREV CLOSE
250.30
HIGH
253.96
LOW
249.12
VOLUME
106.00K
TURNOVER
--
52 WEEK HIGH
287.88
52 WEEK LOW
142.00
MARKET CAP
27.22B
P/E (TTM)
-68.0815
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ONC last week (0707-0711)?
Weekly Report · 11h ago
BeOne gets EU nod for nasopharyngeal cancer therapy
Seeking Alpha · 4d ago
BeOne announces EC approval of Tevimbra in combination with chemotherapy
TipRanks · 4d ago
EUROPEAN COMMISSION APPROVES TEVIMBRA® IN COMBINATION WITH CHEMOTHERAPY AS A FIRST-LINE TREATMENT FOR NASOPHARYNGEAL CARCINOMA
Reuters · 4d ago
BEONE MEDICINES AG - TEVIMBRA PLUS CHEMOTHERAPY WELL TOLERATED
Reuters · 4d ago
R&D Day Pipeline Updates Might Change The Case For Investing In BeOne Medicines (ONC)
Simply Wall St · 4d ago
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), Amgen (AMGN) and BeOne Medicines (ONC)
TipRanks · 4d ago
Stock Picks From Seeking Alpha's June 2025 New Analysts
Seeking Alpha · 6d ago
More
About ONC
BeOne Medicines Ltd., formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Webull offers BeOne Medicines AG (ADR) stock information, including NASDAQ: ONC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONC stock methods without spending real money on the virtual paper trading platform.